Development & manufacture of pharmaceutical products for the treatment of substance abuse disorcer. Nida REF. No. N01DA-16-8926; POP: 09/18/2016 - 09/17/2021.
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN271201600028C
- Awardee
-
Murty Pharmaceuticals, Inc. UEI DNJBTJ3XBQM6
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,644,780
Award facts
- Opportunity
-
- Development and Manufacture of Pharmaceutical Products for Treatment of Substance Abuse Disorder Award Notice · Posted Sep 19, 2016
- Contract value 21% obligated
-
- $1,644,780.48 Current, with exercised options
- $7,831,331.48 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Lexington, KY 40509, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$341,880 | |
| Funding Only Action | -$199,286 | |
| Funding Only Action | -$4,373 | |
| Supplemental Agreement for work within scope | $317,023 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $249,941 | |
| Exercise an Option | $97,575 | |
| Exercise an Option | $93,608 | |
| Exercise an Option | $308,187 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $310,537 | |
| Funding Only Action | $97,295 | |
| Funding Only Action | $331,177 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $384,977 |
Show all 16
About this award
The National Institute on Drug Abuse (NIDA) awarded a $7,831,331.48 cost-plus-fixed-fee contract to Murty Pharmaceuticals, Inc., a minority-owned small disadvantaged business, for the development and manufacturing of pharmaceutical products to treat substance abuse disorders. The 5-year contract, which runs from September 18, 2016 to September 17, 2021, includes the production of morphine sulfate pellets and methamphetamine hydrochloride in support of NIDA's efforts to develop new medications for substance use disorders. Murty Pharmaceuticals will perform stability studies, cGMP manufacturing, quality control testing, and other activities at its facility in Lexington, Kentucky. This award is part of a larger $45 million indefinite delivery, indefinite quantity (IDIQ) contract from the National Institutes of Health (NIH) for drug formulation and manufacturing in support of various agency research programs.
Quick answers
Who was awarded contract HHSN271201600028C?
HHSN271201600028C was awarded to Murty Pharmaceuticals, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 16, 2016.
How much is contract HHSN271201600028C worth?
The government has obligated $1,644,780 on HHSN271201600028C. Its potential value, with all options, is $7,831,331.
Was contract HHSN271201600028C competed?
The extent of competition for HHSN271201600028C was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award